AFAyman Fareed

Ayman Fareed

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ayman Fareed has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effect of heroin use on changes of brain functions as measured by functional magnetic resonance imaging, a systematic review

    by Ayman Fareed, Jungjin Kim, Bethany Ketchen, Woo Jin Kwak, Danzhao Wang, Hilaire Shongo-Hiango, Karen Drexler

    In this study the authors focus on reviewing imaging studies that used resting state functional magnetic resonance imaging for individuals with a history of heroin use. This review study compiled existing research addressing the effect of heroin use on decision making by reviewing available functional neuroimaging data. Systematic review of the literatures using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist. Eligible articles were retrieved through a computer-based MEDLINE and PsycINFO search from 1960 to December 2015 using the major medical subject headings “heroin, fMRI” (all fields). Only English language was included. Thirty-seven articles were initially included in the review. Sixteen were excluded because they did not meet the inclusion criteria. The results of 21 articles that met all the inclusion criteria were presented. Based on the 21 studies included in the current review, there is evidence that heroin use may have a direct and damaging effect on certain brain functions and that these changes may be associated with impulsive and unhealthy decision making. From the review of these studies, the authors understand that a longer duration of heroin use may be associated with more damaging effects on brain functions. The authors also understand that these brain changes could last long after abstinence, which may increase the risk of relapse to heroin use. More research is needed to create a biomarker map for patients with heroin use disorder that can be used to guide and assess response to treatment.


  • Open Access

    Comorbid Post Traumatic Stress Disorder, Pain and Opiate Addiction

    by Bethany Ketchen, Pamela Eilender, Ayman Fareed


  • Comorbid Post Traumatic Stress Disorder, Pain and Opiate Addiction

    by Bethany Ketchen, Pamela Eilender, Ayman Fareed, Kimberly Tarrance

  • Reversal of overdose on fentanyl being illicitly sold as heroin with naloxone nasal spray: A case report

    by Ayman Fareed, Ann Marie Buchanan‐Cummings, Kelli Crampton, Angela Grant, Karen Drexler

    Background: This is a case report describing a reversal of fentanyl overdose with naloxone nasal spray. The patient was not aware that he overdosed on fentanyl being sold as heroin.Methods: The Veterans Health Administration (VHA) has implemented an initiative to provide education for veterans, their families, friends and significant others about opioid overdose and use of naloxone reversal kits. The Atlanta VA Medical Center adopted this program to reduce the risk of opioid overdose in high risk patients.Results: Over the past year, we provided educational sessions for 63 veterans and their families. We also prescribed 41 naloxone kits. We have received three reports of opioid overdose reversal with use of naloxone kits prescribed by the Atlanta VA Medical Center.Conclusions and Scientific significance: The authors recommend that public health administrators and policy makers advocate for the implementation of these programs to reduce the rising number of overdose death in the United States and worldwide. (Am J Addict 2015;24:388 –390)


  • Factors Affecting Norbuprenorphine Level in Monitoring Clinical Outcome for Buprenorphine-maintained Patients

    by Ayman Fareed, Kelly Scheinberg, Sreedevi Vayalapalli, Steven Stout, Robin Rn Gale, Aalok Chandora, Karen Drexler

    Background: We conducted an observational retrospective chart review to determine whether buprenorphine or norbuprenorphine levels could predict treatment outcomes. Methods: Of the 174 patients treated in the clinic between 2006 and 2012, 123 were excluded from the study because they did not have a buprenorphine/norbuprenorphine level done at the time of data collection. Thus, 51 patient charts were selected for review. Results: The multiple regression analysis of the predictable variables for positive urine drug screen (UDS) before and after the level showed that norbuprenorphine level (P=0.018 before and P=0.02 after the level) and the primary drug of addiction (P=0.047 before and P=0.01 after the level) are significantly associated with positive UDS for opiates before and after the level (R2=0.06 and R2=0.09, respectively). The multiple regression analysis of the predictable variables for norbuprenorphine level showed that age (P=0.01), race (P=0.006), hepatitis C status, (P=0.006), primary drug of addiction (P=0.0001), and buprenorphine dose (P=0.0003) are significantly associated with higher levels of norbuprenorphine (R2=0.70). The positive UDS for cocaine (P=0.02) before the level is significantly associated with lower norbuprenorphine level (R2=0.70). Conclusions and Scientific Significance: This study suggests that norbuprenorphine levels could be used to guide dosing of buprenorphine, as well as determining whether taking buprenorphine would continue to be beneficial or whether a full agonist may be needed. This study opens the door for further studies on how buprenorphine levels may be used to guide treatment in the clinical setting.


  • QTc interval prolongation for patients in methadone maintenance treatment: a five years follow-up study

    by Ayman Fareed, Sreedevi Vayalapalli, Kelly Scheinberg, Robin Gale, Jennifer Casarella, Karen Drexler

    Background: QTc prolongation for patients in methadone maintenance treatment (MMT) has been reported. In this study we wanted to identify the predictor factors for QTc prolongation >500 ms and other medical risk factors for mortality in this population. Methods: A retrospective chart review study with 55 patients who had previously been included in our performance improvement project and who were eligible to be reviewed. A linear regression model with one-sided p value was used for data analysis. Results: Over 5 years, 41% to 56% of patients had QTc > 450 and 500 ms. This QTc prolongation from baseline showed statistical significance (p < 0.0001). Being diagnosed with congestive heart failure (CHF), elevated HgA1c level and recent cocaine use were significantly associated with QTc prolongation >500 ms. The model as a whole showed statistical significance (F = 3.50, p = 0.02). Being diagnosed with CHF and elevated HgA1c level was significantly associated with mortality. The model as a whole also showed statistical significance (F = 4.63, p = 0.01). Conclusions: This study confirms that methadone may be associated with QTc prolongation. It identified three risk factors for significant QTc prolongation for patients on MMT which are recent cocaine use, uncontrolled blood glucose and CHF. Two of these three risk facts (uncontrolled blood glucose and CHF) were associated with mortality in this cohort. Patients with these medical co-morbidities may benefit from EKG screening and aggressive treatment of the medical risk factors while taking MMT.


  • Predictors of Diabetes Mellitus and Abnormal Blood Glucose in Patients Receiving Opioid Maintenance Treatment

    by Ayman Fareed, Johnita Byrd-Sellers, Sreedevi Vayalapalli, Karen Drexler, Lawrence Phillips

    Buprenorphine is a partial opioid agonist and may have less impact on the risk of developing diabetes mellitus (DM) compared to full opioid agonists like methadone. We conducted an observational retrospective study to investigate the predictable factors for impaired glucose tolerance and predisposition to DM in two groups of opiate addicts receiving long-term methadone maintenance treatment (MMT) [n = 58] or buprenorphine maintenance treatment (BMT) [n = 61]. In our cohort, being African American, hepatitis C positive status, elevated AST, and ALT, and being on methadone were significantly correlated to being diagnosed with DM. Among all those factors, being on methadone was most significantly related to being diagnosed with DM (χ² = 3.9888, p-value = .0458). The BMI was the only factor that was significantly correlated to having abnormal A1c level (χ² = 6.4229, p-value = .0113). Buprenorphine may be less likely to contribute to the development of DM than methadone. More research is needed to understand the link between opioids and DM.


  • Comorbid Posttraumatic Stress Disorder and Opiate Addiction: A Literature Review

    by Ayman Fareed, Pamela Eilender, Michael Haber, James Bremner, Natasha Whitfield, Karen Drexler

    Treatment of comorbid posttraumatic stress disorder (PTSD) and opioid dependence has been a challenge for many clinicians. There are limited evidence-based guidelines for treatment of this comorbidity. Symptoms of PTSD and opiate dependence may converge, and it is sometimes difficult to differentiate between both conditions. For example, opioid withdrawal symptoms may mimic the hypervigilance and exacerbated startle response of patients with PTSD. A common neurobiologic circuit is suggested for the pathophysiologic mechanism of this comorbidity. There is evidence that opioid substitution therapy may improve treatment outcomes for opioid addiction in patients with comorbid PTSD and opioid dependence. Evidence-based psychotherapeutic intervention is recommended for this population to improve the psychological outcome as well. Combining opioid substitution therapy with evidence-based cognitive behavioral therapy designed for individuals with comorbid PTSD and substance abuse (e.g., Seeking Safety) may improve treatment outcomes in this population. More research is needed to understand the underlying mechanisms for this comorbidity and to improve treatment response.


  • Open Access

    Hypogonadism and Low Testosterone Levels as a Side Effect of Methadone and Buprenorphine

    by Ayman Fareed

    Keywords: Buprenorphine; Metadone; Testis; Histopathology


  • Effect of Buprenorphine Dose on Treatment Outcome

    by Ayman Fareed, Sreedevi Vayalapalli, Jennifer Casarella, Karen Drexler

    The goal of this meta-analysis is to provide evidence based information about proper dosing for buprenorphine maintenance treatment to improve treatment outcome. To be selected for the review and inclusion in the meta-analysis, articles had to be randomized, controlled, or double-blind clinical trials, with buprenorphine as the study drug; the length of buprenorphine maintenance treatment had to be 3 weeks or longer; doses of buprenorphine had to be clearly stated; outcome measures had to include retention rates in buprenorphine treatment; outcome measures had to include illicit opioid use based on analytical determination of drugs of abuse in urine samples as outcome variables; and outcome measures had to include illicit cocaine use based on analytical determination of drugs of abuse in urine samples as outcome variables. Twenty-nine articles were excluded because they did not meet the inclusion criteria. The authors present the results of 21 articles that met inclusion criteria. The higher buprenorphine dose (16–32 mg per day) predicted better retention in treatment compared with the lower dose (less than 16 mg per day) (P = .009, R2 adjusted = 0.40), and the positive urine drug screens for opiates predicted dropping out of treatment (P = .019, R2 Adjusted = 0.40). Retention in treatment predicted less illicit opioid use (P = .033, R2 Adjusted = 0.36), and the positive urine drug screens for cocaine predicted more illicit opioid use (P = .021, R2 Adjusted = 0.36). Strong evidence exists based on 21 randomized clinical trials that the higher buprenorphine dose may improve retention in buprenorphine maintenance treatment.